Review articleMacrolides and ketolides: azithromycin, clarithromycin, telithromycin
Section snippets
Chemistry
Erythromycin is a macrolide antibiotic whose structure consists of a macrocyclic 14-membered lactone ring attached to two sugar moieties (a neutral sugar, cladinose, and an amino sugar, desosamine). In the acidic environment of the stomach, it is rapidly degraded to the 8,9-anhydro-6,9-hemiketal and then to the 6,9,9,12-spiroketal form. The hemiketal intermediate may be responsible for the gastrointestinal adverse effects associated with erythromycin [1].
Clarithromycin (6-O-methylerythromycin)
Mechanism of action and resistance
The macrolide and ketolide antimicrobials exert their antibacterial effects by reversibly binding to the 50s subunit of the bacterial ribosome. This interaction inhibits RNA-dependent protein synthesis by preventing transpeptidation and translocation reactions [2]. Both the macrolides and ketolides bind to domain V of the 23S ribosomal RNA (rRNA) [7]. The ketolides bind with a 10- to 100-fold higher affinity to the ribosome than erythromycin. Additionally, the ketolides, unlike the macrolides,
Pharmacokinetics
The structural alterations to the erythromycin base used to synthesize the advanced macrolides and ketolides result in improved pharmacokinetic properties. Because erythromycin is degraded in an acidic environment, oral bioavailability is variable and depends on the preparation studied. Clarithromycin and azithromycin are more acid-stable and have greater oral bioavailability (55% and 37%, respectively) [14], [15]. When taken with meals the peak plasma concentration of clarithromycin
Spectrum of activity
Guidelines from the National Committee for Clinical Laboratory Standards provide the following interpretation of in vitro MICs for clarithromycin and azithromycin [38]. For S pneumoniae, susceptibility breakpoints are less than or equal to 0.25 mg/L and less than or equal to 0.5 mg/L for clarithromycin and azithromycin, respectively. The corresponding resistance breakpoints are greater than or equal to 1 mg/L and greater than or equal to 2 mg/L. The breakpoint for susceptibility against
Upper respiratory tract infections
Clarithromycin, azithromycin, and telithromycin are effective against the most frequently isolated bacterial causes of pharyngitis, otitis media, and sinusitis. A 5-day course of either the extended-release formulation of clarithromycin, azithromycin, or telithromycin is equally as effective as a 10-day course of penicillin for the treatment of streptococcal pharyngitis [3], [54], [55], [56]. In comparative trials, clarithromycin has proved to be equivalent to amoxicillin,
Adverse effects
Azithromycin, clarithromycin, and telithromycin are well tolerated. Gastrointestinal intolerance is the primary adverse side effect of these agents, but occurs at a significantly reduced rate when compared with erythromycin [41]. The most common adverse effects reported with azithromycin were diarrhea (3.6%); nausea (2.6%); abdominal pain (2.5%); and headache or dizziness (1.3%). Laboratory abnormalities were infrequent and minor including transient increases in transaminases in 1.5% of
Drug interactions
Several reviews have discussed drug interactions between either clarithromycin or azithromycin and other agents [34], [162]. Clarithromycin, like erythromycin, is oxidized by the cytochrome P-450 system, primarily the CYP3A4 subclass of hepatic enzymes [163]. This converts clarithromycin to a nitrosalkalane metabolite that forms an inactive metabolite-enzyme complex by binding to the iron of the CYP3A4 enzyme [34]. This interaction inhibits the CYP3A4 enzymes resulting in decreased clearance of
Summary
The advanced macrolides (azithromycin and clarithromycin) and ketolides (telithromycin) are structural analogues of erythromycin that have similar mechanisms of action. These antimicrobials have several distinct advantages over erythromycin including the following: improved oral bioavailability, longer half-life allowing once- or twice-daily administration, higher tissue concentrations, enhanced antimicrobial activity, and less gastrointestinal adverse effects. Clarithromycin and azithromycin
References (170)
- et al.
Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting
Mayo Clin Proc
(2003) - et al.
Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview
Diagn Microbiol Infect Dis
(1992) - et al.
Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment
Int J Antimicrob Agents
(2003) - et al.
In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance
J Infect Chemother
(2003) - et al.
Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study
Clin Ther
(2003) - et al.
Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group
Clin Ther
(1999) - et al.
Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis
Clin Ther
(2000) - et al.
Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis
Am J Otolaryngol
(1999) - et al.
Comparative efficacy of clarithromycin modified-release and clarithromycin immediate-release formulations in the treatment of lower respiratory tract infection
Clin Ther
(2001) - et al.
An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis
Clin Ther
(2002)
Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis
Clin Ther
Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis
Clin Ther
Comparison of once- and twice-daily clarithromycin in the treatment of adults with severe acute lower respiratory tract infections
Clin Ther
Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis
Clin Ther
A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes
Clin Ther
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia
Respir Med
A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia
Clin Ther
A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia
Clin Ther
Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis
Chest
Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis
Respir Med
Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia
Clin Microbiol Infect
Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis
Respir Med
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia
Chest
A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia
Clin Ther
Macrolides with gastrointestinal motor stimulating activity
J Med Chem
Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles
Ann Pharmacother
Clarithromycin and azithromycin: new macrolide antibiotics
Clin Pharm
Telithromycin: the first of the ketolides
Ann Pharmacother
Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site
J Antimicrob Chemother
Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells
Curr Microbiol
The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA
Mol Microbiol
Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA
Mol Microbiol
mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae
Antimicrob Agents Chemother
Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification
Antimicrob Agents Chemother
Ketolides lack inducibility properties of MLS(B) resistance phenotype
J Antimicrob Chemother
The pharmacokinetics of azithromycin in human serum and tissues
J Antimicrob Chemother
The development of macrolides: clarithromycin in perspective
J Antimicrob Chemother
Pharmacokinetics and tolerability of extended-release clarithromycin
Clin Ther
The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension
J Antimicrob Chemother
Clinical toleration and safety of azithromycin
Am J Med
Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers
Chemotherapy
Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin
Scand J Infect Dis
Intravenous azithromycin
Ann Pharmacother
Metabolism and disposition of clarithromycin in man
Drug Metab Dispos
Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers
J Antimicrob Chemother
Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses
Antimicrob Agents Chemother
The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans
J Antimicrob Chemother
Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
Antimicrob Agents Chemother
Cited by (170)
U-disk portable photoelectrochemical sensor based on bifunctional poly(o-phenylenediamine) for on-site detection of erythromycin
2024, Sensors and Actuators B: ChemicalPythium insidiosum: In vitro oomicidal evaluation of telithromycin and interactions with azithromycin and amorolfine hydrochloride
2024, Journal of Medical MycologyElectrocatalytic behaviour of self-assembled Cu-chitosan/f-MWCNT on glassy carbon electrode for detection of erythromycin in various samples
2023, Sensing and Bio-Sensing ResearchEfficacy and mechanism of actions of natural antimicrobial drugs
2020, Pharmacology and TherapeuticsTherapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement
2024, Molecular Diversity